Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7007140 | 0.86 | HDAC8 (0.44) | PNPHDAC8PLA2G7KMT2ATDP1 | |
| SCHEMBL4418633 | 0.83 | ALDH1A1 (0.53) | PNPKMT2AALDH1A1CYP2C9HPGD | |
| SCHEMBL7007907 | 0.82 | PNP (0.55) | PNPPLA2G7 | |
| SCHEMBL4415229 | 0.81 | PLA2G7 (0.43) | PNPPLA2G7KMT2ATDP1 | |
| SCHEMBL11450005 | 0.81 | KMT2A (0.49) | KMT2ATDP1PDE3BPDE3AALDH1A1 | |
| SCHEMBL4423230 | 0.81 | DAO (0.51) | KMT2ATDP1PDE3BPDE3A | |
| SCHEMBL9105430 | 0.77 | KMT2A (0.42) | KMT2ATDP1 | |
| SCHEMBL10918304 | 0.77 | ERAP1 (0.60) | KMT2ATDP1ALDH1A1 | |
| SCHEMBL10981672 | 0.77 | TDP1 (0.46) | KMT2ATDP1ALDH1A1 | |
| SCHEMBL9108804 | 0.77 | DAO (0.47) | KMT2ATDP1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028955-B1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
| EP-1028955-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham p.l.c. (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024420-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1999-05-20 | — | — | WO | disclosed |
| US-4216318-A | HISTAMINE HZ-ANTAGONISTS, ISOCYTOSINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
| US-4154834-A | HETEROCYCLIC-(THIO)ALKYLAMINO SUBSTITUTED-4-PYRIMIDONE OR -THIONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | PNP 24/4885HDAC8 3223/4885PLA2G7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.